Smoking Cessation Methods for Cancer Patients

Overseen By Mark Zehner

Age: 18+

Sex: Any

Trial Phase: Phase 4

Sponsor: University of Wisconsin, Madison

Must not be taking: Antipsychotics

Disqualifiers: Suicidal ideation, Incarceration, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Approved in 3 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: 19

Duration: 12 weeks

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests two methods to help cancer patients quit smoking. One group will undergo a high-intensity treatment with 12 weeks of varenicline (a prescription drug for smoking cessation) and receive 7 cancer-focused coaching sessions. The other group will follow a standard approach using a nicotine patch for 2 weeks and participate in 3 phone coaching calls. The trial aims to determine which method helps more people quit smoking after 26 weeks, emphasizing effectiveness and fairness across different patient groups. This trial suits those diagnosed with cancer in the last 3 years who have recently smoked cigarettes and are ready to quit within the next 60 days. As a Phase 4 trial, the treatment is already FDA-approved and proven effective, allowing researchers to understand how it benefits more patients.

Do I need to stop my current medications to join the trial?

The trial information does not specify whether you need to stop taking your current medications. However, it does mention that participants should not be currently receiving treatment for certain mental health disorders like bipolar disorder or schizophrenia.

What is the safety track record for these treatments?

Research has shown that varenicline, a medication to help people quit smoking, is generally well-tolerated. In a study with cancer patients, varenicline helped many participants stop smoking. Most people tolerate it well, but some risks exist.

The FDA notes that varenicline can interact with alcohol and may rarely cause mood changes or vivid dreams. Some individuals might experience nausea or trouble sleeping, but these effects are usually mild. Nicotine patches, another common method to quit smoking, are also generally safe but can cause skin irritation at the application site.

Both treatments have their pros and cons, but they have been tested for safety in many people, including those with cancer. Prospective trial participants should consult their healthcare provider to determine which option might be better. ^{1 2 3 4 5}

Why are researchers enthusiastic about this study treatment?

Researchers are excited about these treatments for smoking cessation in cancer patients because they offer tailored approaches that go beyond traditional methods. Unlike the standard low-intensity treatment, which includes a short course of nicotine patches and minimal counseling, the high-intensity option provides an extended 12-week varenicline therapy combined with seven counseling sessions specifically designed for cancer patients. Varenicline works by targeting nicotine receptors in the brain, reducing cravings and withdrawal symptoms more effectively than nicotine replacement therapies. This personalized approach is believed to enhance quitting success rates among cancer patients, offering hope for better outcomes.

What evidence suggests that this trial's treatments could be effective for smoking cessation in cancer patients?

Research shows that varenicline, which participants in this trial may receive as part of the high-intensity, cancer-targeted smoking cessation treatment, helps cancer patients quit smoking more effectively. Studies have found that patients taking varenicline succeed more often at quitting than those using standard treatments. In this trial, the standard treatment arm includes a low-intensity approach with nicotine patch therapy and standard telephone counseling. Evidence also suggests that stopping smoking around the time of a cancer diagnosis can improve survival rates and lessen the side effects of cancer treatments. Longer use of varenicline may be especially helpful for cancer patients because it supports mood and thinking, making it easier to quit. Overall, these findings suggest that varenicline is a strong option for helping cancer patients stop smoking. ^{6 7 8 9 10}

Who Is on the Research Team?

Danielle E McCarthy, PhD

Principal Investigator

University of Wisconsin, Madison

Are You a Good Fit for This Trial?

This trial is for adult cancer patients who were diagnosed within the last 3 years and are looking to quit smoking. It's not specified who can't join, but typically those with health conditions that may interfere with the treatment or assessment might be excluded.

Inclusion Criteria

Received care from a participating oncology clinic in the past year

I was diagnosed with cancer within the last 3 years.

Has a current tobacco use status

Exclusion Criteria

Suicide attempt in the past year

I understand the study procedures and risks involved.

No current suicidal ideation

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either 12 weeks of varenicline treatment with 7 smoking cessation coaching calls or 2 weeks of nicotine patch therapy with 3 phone coaching calls

12 weeks

7 visits (virtual) for high-intensity group, 3 visits (virtual) for low-intensity group

Follow-up

Participants are monitored for smoking abstinence and other outcomes

30 weeks

Follow-up assessments at 12 and 26 weeks post target quit date

What Are the Treatments Tested in This Trial?

Interventions

• Cancer-Targeted Telephone Counseling
• Standard Telephone Counseling
• Transdermal Nicotine Patch
• Varenicline

Trial Overview The study compares two smoking cessation methods: an enhanced treatment with varenicline pills and targeted coaching calls, versus a standard approach using nicotine patches and regular phone counseling. The goal is to see which method helps more people quit smoking after 26 weeks.

How Is the Trial Designed?

Group I: High-Intensity, Cancer-Targeted Smoking Cessation Treatment Experimental Treatment 3 Interventions

12 weeks of varenicline therapy, 7 counseling sessions targeted to cancer patients, and information about quitline and SmokefreeTXT services

Group II: Low-Intensity Standard Smoking Cessation Treatment Active Control 3 Interventions

2 weeks of nicotine patch therapy, 3 telephone counseling sessions, and information about quitline and National Cancer Institute text messaging support services (SmokefreeTXT)

Varenicline is already approved in United States, European Union, Canada for the following indications:

Approved in United States as Chantix for:

• Smoking cessation
• Dry eye disease

Approved in European Union as Champix for:

• Smoking cessation

Approved in Canada as Champix for:

• Smoking cessation

Who Is Running the Clinical Trial?

University of Wisconsin, Madison

Lead Sponsor

Trials

1,249

Recruited

3,255,000+

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+

Published Research Related to This Trial

Varenicline, an FDA-approved medication for smoking cessation, significantly increases the chances of quitting smoking, with continuous abstinence rates 2.7 to 3.1 times higher than placebo over a 52-week period after 12 weeks of treatment.

In addition to helping smokers quit, varenicline reduces cravings and withdrawal symptoms, making it a valuable option for those looking to stop smoking.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Varenicline: a review of its use as an aid to smoking cessation therapy. Keating, GM., Siddiqui, MA.[2018]

Varenicline (Champix) is a newly approved medication for smoking cessation that acts as a partial agonist of nicotinic receptors, offering a different mechanism of action compared to traditional therapies like nicotine replacement and bupropion.

Recent studies indicate that varenicline is effective in helping individuals quit smoking and may have advantages over existing treatments, although potential side effects are also discussed.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Drug of the month. Varenicline (Champix)]. Vandemergel, X.[2015]

Smoking cessation is crucial for health, and psychiatric nurses should actively support patients in using therapies like varenicline (Chantix) to quit smoking.

Recent research has raised safety concerns about varenicline, including its potential links to neuropsychiatric side effects, seizures, and interactions with alcohol, which clinicians need to consider when recommending this treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Clinical Psychopharmacology Update: Additional Safety Concerns for Using Varenicline (Chantix) for Smoking Cessation Treatment. Tobin, TJ., Tobin, ML.[2018]

Varenicline is a highly effective medication for smoking cessation, showing superior efficacy compared to placebo and bupropion in clinical trials involving chronic smokers, and it helps alleviate withdrawal symptoms.

The recommended treatment regimen involves starting varenicline one week before the quit date, with a titration schedule to minimize side effects like nausea, making it a suitable option for smokers who struggle with other cessation aids.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Varenicline: a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist approved for smoking cessation. Lam, S., Patel, PN.[2017]

In a study of 2,682 patients using varenicline for smoking cessation, nausea and vomiting were the most common reasons for discontinuation and the most frequently reported adverse drug reactions, highlighting the need for patient monitoring regarding gastrointestinal side effects.

While some psychiatric events were reported, including anxiety and depression, all cases of suicidal behavior involved patients with prior psychiatric conditions, suggesting that clinicians should closely monitor individuals with such histories when prescribing varenicline.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring study. Kasliwal, R., Wilton, LV., Shakir, SA.[2021]

In a phase 2 study involving 411 healthy smokers, varenicline tartrate at doses of 1.0 mg once and twice daily significantly increased quit rates compared to placebo, with 48.0% and 37.3% quitting respectively, versus only 17.1% for placebo.

Varenicline was well tolerated, with discontinuation rates due to adverse events similar to placebo, indicating it is a safe and effective option for smoking cessation, especially at the 1.0 mg twice daily dose for long-term success.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Nides, M., Oncken, C., Gonzales, D., et al.[2022]

In a review of ten randomized controlled trials involving 3091 participants, varenicline did not show a significant increase in overall psychiatric disorders compared to placebo, with an incidence of 10.7% in the varenicline group versus 9.7% in the placebo group.

While varenicline was associated with a higher incidence of sleep disorders, there were no reported cases of suicidal ideation or behavior in the analyzed studies, suggesting that varenicline is generally safe for smokers without current psychiatric conditions.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis. Tonstad, S., Davies, S., Flammer, M., et al.[2022]

Varenicline is an effective treatment for tobacco addiction, showing improved quit rates compared to other therapies, and is safe for use in both healthy smokers and those with cardiovascular or pulmonary issues, as well as smokeless tobacco users.

While varenicline is generally well-tolerated, there have been concerns about potential neuropsychiatric side effects, leading to updated monitoring guidelines, although most studies did not find a significant link to serious psychiatric symptoms, except for sleep disorders.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Varenicline in smoking cessation. Tonstad, S., Rollema, H.[2017]

In a study of 12,159 patients, varenicline was associated with reported neuropsychiatric events, particularly anxiety, but no significant increase in these events was found over time, suggesting that the drug's safety profile remains largely stable.

While 7-17% of neuropsychiatric events were attributed to varenicline by general practitioners, the analysis did not raise significant safety concerns, indicating that further investigation is needed to clarify the relationship between varenicline and anxiety symptoms.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Neuropsychiatric events with varenicline: a modified prescription-event monitoring study in general practice in England. Buggy, Y., Cornelius, V., Fogg, C., et al.[2021]

Participants who chose varenicline (3,116 individuals) for tobacco cessation had higher abstinence rates at both 3 months (22%) and 6 months (17%) compared to those using nicotine replacement therapy (NRT) (13% at 3 months and 11% at 6 months), indicating that varenicline may be more effective in supporting quitting.

The study found that factors such as increasing age, having health insurance, and the number of counseling sessions were associated with higher rates of abstinence, particularly at 3 months, suggesting that these factors could enhance the effectiveness of quitline services.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Characteristics and abstinence outcomes among tobacco quitline enrollees using varenicline or nicotine replacement therapy. Biazzo, LL., Froshaug, DB., Harwell, TS., et al.[2015]

In a randomized controlled trial, varenicline (Chantix) demonstrated a higher abstinence rate from smoking after one year compared to both bupropion SR (Zyban) and a placebo, indicating its efficacy in treating tobacco dependence.

Despite its effectiveness, varenicline has been associated with serious neuropsychiatric side effects, highlighting the importance of discussing potential risks and benefits with patients considering this treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Treatment of nicotine dependence with Chantix (varenicline). Rankin, KV., Jones, DL.[2015]

Citations

1. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC6936106/

A Randomized Controlled Trial of 24-Weeks of Varenicline for ... Conclusions: Compared to ST, ET varenicline does not increase patient risk and increases smoking cessation rates among patients who adhere to treatment. ...

2. jamanetwork.com jamanetwork.com/journals/jamaoncology/fullarticle/2825372

Survival Outcomes of an Early Intervention Smoking ... This cohort study evaluates the survival outcomes of currently smoking patients with cancer who entered into a smoking cessation treatment program based.

3. sciencedirect.com sciencedirect.com/science/article/pii/S2213538323000802

The effectiveness of smoking cessation interventions after ... [10] Newly diagnosed cancer patients who quit around diagnosis have higher overall survival, higher disease free survival and similar treatment side effect ...

4. mdanderson.org mdanderson.org/newsroom/increasing-doses-of-varenicline-or-nicotine-replacement-helps-pe.h00-159697545.html

Increasing doses of varenicline or nicotine replacement ... A new study from The University of Texas MD Anderson Cancer Center found patients were more likely to quit if their cessation regimen was altered and doses ...

5. clinicaltrials.gov clinicaltrials.gov/study/NCT01756885

Extended Varenicline Treatment for Smoking Among ... Varenicline may be particularly effective for cancer patients given the drug's beneficial effects on affect and cognition. In this trial, 374 cancer patients ...

6. fda.gov fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-updates-label-stop-smoking-drug-chantix-varenicline-include

FDA updates label for stop smoking drug Chantix FDA Drug Safety Communication: FDA updates label for stop smoking drug Chantix (varenicline) to include potential alcohol interaction, rare risk ...

7. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC2962400/

Varenicline for smoking cessation: efficacy, safety, and ... Increasing varenicline to 3 mgs/day improves abstinence rates: A preliminary efficacy report in cancer patients. Paper presented at: Society for Research on ...

8. ncbi.nlm.nih.gov ncbi.nlm.nih.gov/books/NBK534846/

Varenicline - StatPearls - NCBI Bookshelf Varenicline is a medication prescribed to help patients stop smoking, targeting one of the most modifiable risk factors for preventing human disease.

9. cdc.gov cdc.gov/tobacco/campaign/tips/quit-smoking/quit-smoking-medications/how-to-use-quit-smoking-medicines/how-to-use-varenicline.html

How to Use Varenicline | Quit Smoking Varenicline is a pill you take twice a day. You start taking it at least one week before you quit, gradually increasing the dose.

10. clinicaltrials.gov clinicaltrials.gov/study/NCT01756885

Extended Varenicline Treatment for Smoking Among ... Varenicline may be particularly effective for cancer patients given the drug's beneficial effects on affect and cognition. In this trial, 374 cancer patients ...